Effect of Sildenafil on Renin Secretion in Human Subjects
Authors:
Open Access
- 1 September 2002
- journal article
- research article
- Published by Frontiers Media SA in Experimental Biology and Medicine
- Vol. 227 (8) , 620-625
Abstract
Sildenafil is a potent and selective inhibitor of the cyclic GMP-specific phosphodiesterase (PDE5) that is very effective in the treatment of male impotence. It inhibits breakdown of cyclic guanosine monophosphate (cGMP) formed in penile smooth muscle cells in response to stimulation by nitric oxide resulting in muscle relaxation. PDES is widely distributed in the body, being present in the vasculature, platelets, and kidneys. In the kidney, PDE5 is involved in the regulation of sodium excretion and renin secretion. The aim of the present investigation was to investigate the effect of sildenafil, in doses used clinically, on renin secretion in human subjects. The studies were performed in two groups of healthy normotensive subjects: one in which sodium intake was unrestricted, and one in which sodium intake was restricted to 600 mg/day. Blood pressure and heart rate were monitored throughout the study, and blood samples for the measurement of plasma cGMP and cAMP concentrations and plasma renin activity (PRA) were collected. After control measurements, the subjects ingested a capsule containing sildenafil or placebo. Cardiovascular measurements and blood sampling continued for the next 120 min. Sildenafil had only minor cardiovascular effects. Diastolic pressure tended to be lower and heart rate was generally higher after sildenafil than after placebo, but the differences were small. Sildenafil caused a prompt and sustained increase in plasma cGMP concentration and a more gradual increase in plasma cAMP concentration. After the subjects received placebo, there was a progressive decrease in PRA during the 2-hr observation period, presumably reflecting the circadian rhythm in renin secretion. In contrast, PRA failed to decrease after the subjects received sildenafil, thus indicating that sildenafil exerts a stimulatory action on renin secretion. This action on renin secretion may help explain why sildenafil only has minor effect on blood pressure despite the widespread distribution of PDE5 in vascular tissues.Keywords
This publication has 25 references indexed in Scilit:
- Phosphodiesterase 5 inhibitors and nitrergic transmission—from zaprinast to sildenafilEuropean Journal of Pharmacology, 2001
- Sympathetic Activation by SildenafilCirculation, 2000
- Cardiovascular effects of sildenafil citrate and recommendations for its use11Dr. Kloner and Dr. Zusman are speakers and consultants for Pfizer, Inc.The American Journal of Cardiology, 1999
- Use of sildenafil (Viagra) in patients with cardiovascular diseaseJACC, 1999
- Cyclic-3′,5′-nucleotide phosphodiesterase isozymes in cell biology and pathophysiology of the kidneyKidney International, 1999
- SILDENAFIL, A TYPE-5 CGMP PHOSPHODIESTERASE INHIBITOR, SPECIFICALLY AMPLIFIES ENDOGENOUS cGMP-DEPENDENT RELAXATION IN RABBIT CORPUS CAVERNOSUM SMOOTH MUSCLE IN VITROJournal of Urology, 1998
- EFFECTS OF SILDENAFIL ON THE RELAXATION OF HUMAN CORPUS CAVERNOSUM TISSUE IN VITRO AND ON THE ACTIVITIES OF CYCLIC NUCLEOTIDE PHOSPHODIESTERASE ISOZYMESJournal of Urology, 1998
- Cyclic GMP-linked pathway for renin secretionKidney International, 1994
- Circadian rhythms of atrial natriuretic peptide, renin, aldosterone, cortisol, blood pressure and heart rate in normal and hypertensive subjectsJournal Of Hypertension, 1990
- A diurnal rhythm in plasma renin activity in man.Journal of Clinical Investigation, 1966